Novartis | Salg Og Administrasjonskostnader



Selling And Administration Expenses Endring Dato
AbbVie USD 3.29B 562M 2025-03
Amgen USD 1.88B 253M 2024-12
AstraZeneca USD 3.59B 1.96B 2025-03
Bausch Health Companies USD 867M 47M 2025-03
Biogen USD 677.3M 99.6M 2024-12
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Canopy Growth CAD 40.62M 308K 2024-12
Corcept Therapeutics USD 83.37M 9.63M 2024-12
Drreddys Laboratories INR 21.59B 436M 2024-12
Eli Lilly USD 2.36B 62.3M 2025-03
Gilead Sciences USD 1.26B 603M 2025-03
GlaxoSmithKline GBP 2.06B 603M 2025-03
Glaxosmithkline GBP 2.7B 632M 2024-12
Indivior 132M 179M 2025-03
J&J USD 5.11B 1.34B 2025-03
Merck USD 2.53B 319M 2025-03
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Pacira USD 79.61M 5.28M 2024-12
Perrigo USD 234.8M 36.7M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
Prestige Brands USD 64.13M 3.35M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.22B 980M 2025-03
Sanofi EUR 1.24B 1.44B 2024-12
Supernus Pharmaceuticals USD 79.41M 9.66M 2024-12
Zoetis USD 625M 60M 2024-12



Novartis Salg Og Administrasjonskostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.